Anavex Life Sciences
AVXL
180 hedge funds and large institutions have $95.8M invested in Anavex Life Sciences in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 63 increasing their positions, 57 reducing their positions, and 33 closing their positions.
215% more call options, than puts
Call options by funds: $2.65M | Put options by funds: $840K
11% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 57
3.27% less ownership
Funds ownership: 43.15% → 39.88% (-3.3%)
5% less funds holding
Funds holding: 190 → 180 (-10)
24% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 33
41% less capital inflows, than outflows
Capital inflows: $12.7M | Capital outflows: $21.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.39M |
| 3 |
BlackRock
New York
|
+$1.32M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$649K |
| 5 |
Barclays
London,
United Kingdom
|
+$639K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.66M |
| 2 |
Jane Street
New York
|
-$2.15M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2M |
| 4 |
HF
HRT Financial
New York
|
-$1.95M |
| 5 |
Renaissance Technologies
New York
|
-$850K |
AVXL Hedge Fund Activity: Q2 2026 in Review
180 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q2 2026, worth a combined $95.8M — down 22% from $123M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of AVXL and 25 opened new positions — a net loss of 8 holders — while 57 trimmed existing stakes and 63 added.
The largest buyer was Federated Hermes, adding an estimated $1.6M. The largest seller was State Street, cutting an estimated $7.66M.
- 180 institutional investors held Anavex Life Sciences (AVXL) as of Q2 2026, down from 190 in Q1 2026.
- Funds reported $95.8M of Anavex Life Sciences stock for Q2 2026, down 22% quarter-over-quarter.
- 25 funds opened new Anavex Life Sciences positions in Q2 2026 and 33 closed out, a net change of -8 holders.
- The largest Anavex Life Sciences buyer in Q2 2026 was Federated Hermes, an estimated $1.6M added.
- The largest Anavex Life Sciences seller in Q2 2026 was State Street, an estimated $7.66M sold.
Based on aggregated 13F filings for Q2 2026.